Trial Profile
A Randomized , Double Blind, Placebo Controlled, 3-Arm Parallel Design Study to Evaluate the Effects of BPN14770 in Patients With Early Stage Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs Zatolmilast (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms Tetra PICASSO AD
- Sponsors Tetra Therapeutics
- 07 Jun 2023 Status changed from active, no longer recruiting to completed.
- 26 May 2020 Status changed from active, no longer recruiting to completed, according to a Tetra Therapeutics media release.
- 06 Mar 2020 According to a Tetra Therapeutics media release, topline results are expected later this month.